Publication | Open Access

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Ifct-1501 Maps2Immune Checkpoint InhibitorPleural DiseaseCancer TreatmentOncologyRadiation OncologyRadiologyHealth Sciences